PYC Thera. (PYC) is held by 5 ASX ETFs. Over the last 3 months it rose 60.3%: on $10,000, +$6026. We explain 5 big moves in that time.
About PYC
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.5b
- Held by5 ETFs
- Big moves5 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +7.9%18 Sep 2026· Contract
PYC Therapeutics rose on momentum from a clinical milestone — dosing the first patient in its PKD open-label extension study — amplified by a run of bullish media coverage highlighting strong recent share price performance and pipeline progress.
- +6.1%2 Sep 2026· Earnings Beat
PYC Therapeutics shares rose after its full-year results showed a narrowed net loss, which was received positively by the market in the days following the annual report release.
- −5.9%21 Aug 2026· Sector Flow
PYC Therapeutics fell alongside a broad sell-off in the Australian healthcare sector, with no company-specific news to explain the move.
- +9.6%4 Aug 2026· Operational
PYC Therapeutics shares rose 9.62% on August 4, 2026, as the company's kidney trial advanced into multiple dosing, attracting investor attention.
- +6.2%3 Aug 2026· Sector Flow
PYC Therapeutics rose in line with a broad healthcare sector rally on the ASX, which was up over 2.3% on the same day.
Held by 5 ETFs
Of every $10,000 in each fund, how much is in PYC today.
Why did PYC rise 7.9% on 18 Sep 2026?
PYC Thera.
PYC Therapeutics rose on momentum from a clinical milestone — dosing the first patient in its PKD open-label extension study — amplified by a run of bullish media coverage highlighting strong recent share price performance and pipeline progress.
No formal ASX announcement was detected in the 18-hour window, but news from 11 September reporting the first patient dosed in the PKD open-label extension study is a meaningful clinical milestone that likely continued to attract buying interest into the following week. Multiple Kalkine articles in the days leading up to the move kept PYC in front of retail investors, reinforcing momentum. The sector index (^AXHJ) moved only +0.36% — well below the threshold — confirming this is stock-specific rather than a broad healthcare sector rotation, and the moderate volume ratio (1.5x) is consistent with news-driven retail buying rather than institutional block activity.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
Sector / macro signals
What it did to the 5 ETFs holding PYC
On $10,000 in each fund, at the weight it holds today